Cognitive Enhancement Through Transcranial Laser Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

February 21, 2016

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Healthy ParticipantsMild Cognitive Impairment
Interventions
DEVICE

LLLT

The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA).

DEVICE

Placebo

The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). However, the placebo group will receive approximately 1/12th of the cumulative energy density as the treatment group.

Trial Locations (1)

78712

University of Texas at Austin, Austin

All Listed Sponsors
lead

University of Texas at Austin

OTHER

NCT02851173 - Cognitive Enhancement Through Transcranial Laser Therapy | Biotech Hunter | Biotech Hunter